JGC
SAGE

J. Goldman & Co’s Sage Therapeutics SAGE Stock Holding History

J. Goldman & Co’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-116,842
Closed -$1.27M – 597
2024
Q2 		$1.27M Buy
+116,842
New +$1.5M 0.04% 287
2017
Q2 		– Sell
-9,300
Closed -$661K – 399
2017
Q1 		$661K Sell
9,300
-11,900
-56% -$697K 0.03% 270
2016
Q4 		$1.08M Sell
21,200
-29,400
-58% -$1.39M 0.07% 216
2016
Q3 		$2.33M Buy
50,600
+4,100
+9% +$167K 0.13% 170
2016
Q2 		$1.4M Sell
46,500
-55,500
-54% -$1.85M 0.07% 230
2016
Q1 		$3.27M Buy
+102,000
New +$3.59M 0.2% 136

Other funds holding SAGE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

J. Goldman & Co's SAGE Position: Q3 2024 in Review

J. Goldman & Co sold out of Sage Therapeutics (SAGE) in Q3 2024, closing a stake of 116,842 shares — an estimated $1.27M sold.

J. Goldman & Co first reported a position in SAGE in Q1 2016 and held it in 6 quarters. The position peaked at $3.27M in Q1 2016. 176 funds tracked by Wall St. Rank hold SAGE as of Q3 2024.

  • J. Goldman & Co reported no remaining Sage Therapeutics position as of Q3 2024 after selling out during the quarter.
  • J. Goldman & Co sold 116,842 Sage Therapeutics shares in Q3 2024, an estimated $1.27M.
  • J. Goldman & Co first reported a position in Sage Therapeutics in Q1 2016 and held it in 6 quarters.
  • J. Goldman & Co's Sage Therapeutics position peaked at $3.27M in Q1 2016.
  • 176 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2024.

Based on J. Goldman & Co's 13F filing for Q3 2024, filed 14 Nov 2024.